The sale sizes are too small relative to market cap to be informative — treat as routine insider liquidity. No CEO/CFO selling and no buying signals present. Monitor the next QURE catalyst (pipeline updates for AMT-130 / Huntington's gene therapy) as the real driver; insider activity alone does not warrant action here.
Price Chart
Executive Summary
Two directors sold a combined ~$148K in QURE stock over the past week, with the larger June 11 cluster showing 6 directors plus the Chief Customer Officer selling a total of ~$775K at $27.06 — nearly all sales are small, pre-planned-looking dispositions in the 1.9K–2.7K share range. These sales represent ~0.05% of market cap, which is trivial and routine. The broader 7-day insider-trade picture is overwhelmingly SELL-side with no material open-market buying, but the dollar amounts are miniscule for a $1.7B biotech and likely reflect periodic stock-vesting / 10b5-1-generated sales, not a coordinated bearish signal.
Key Financial Metrics
Key Facts
- Insider cluster over 7 days: Chief Customer & Strategy Officer + 6 directors sold on June 11 at $27.06, total ~$775K
- June 10 director grants (13,980 shares each to multiple directors at $0) were non-cash awards — no economic signal
- All individual sales are in the $50K–$430K range; combined ~$775K is ~0.05% of $1.7B market cap
- No C-suite CEO, CFO, or COO participated in the sales — mostly Director-level disposals
- Multiple Directors simultaneously exercised options (Gut Robert: M-exercise + same-day S-sale at $26.07) consistent with cashless exercise / tax-motivated sale pattern
Financial Impact
Total insider open-market sales of ~$148K (smaller cluster) + ~$775K (June 11 cluster) = ~$923K combined, or ~0.054% of $1.7B market cap
Risk Factors
- If a larger C-suite sale emerges in the next filing window, the pattern could shift from routine to concerning
- Gene therapy clinical trial setbacks or regulatory delays remain the primary fundamental risk for QURE — insider trading does not speak to this
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1781301885155 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access